BioSpace News Archive

Small Pharma Inc. today announces that it has completed enrollment in the Phase IIa clinical trial of its intravenous (“ IV ”) formulation of N, N-dimethyltryptamine (“ DMT ”) candidate, SPL026, with psychotherapy for the treatment of Major Depressive Disorder (“ MDD ”).

AnPac Bio-Medical Science Co., Ltd. announced that on September 16, 2022, the Company filed a request for a hearing before the NASDAQ Hearings Panel to present its financial data including Shareholders’ Equity and plan with the applicable listing requirements.

GNT Pharma Inc. announces that the independent data monitoring committee (IDMC) for ENIS-3 (Efficacy and safety of Nelonemdaz for Ischemic Stroke) has completed a pre-specified interim analysis encompassing 227 acute ischemic stroke patients treated with placebo or nelonemdaz within 8 hours of onset in China.

The Muscular Dystrophy Association announced today the awarding of 70 new grants totaling over $17 million toward neuromuscular disease research.

PolyPid Ltd. today announced the peer-reviewed publication of positive clinical data from the previously completed Phase 2 study of D-PLEX 100 for the prevention of surgical site infections (SSIs) in abdominal surgery.

OncoNano Medicine, Inc. today announced that Chief Medical Officer Kartik Krishnan, MD, PhD, will present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

Gamida Cell Ltd. today announced that Abigail “Abbey” L. Jenkins, MS, has joined as President & CEO.

Provention Bio, Inc. today announced that the Company has appointed Sarah O’Brien as Chief People Officer.

Adhera Therapeutics, Inc. (OTCQB: ATRX) (“Adhera” or the “Company”), a clinical stage biopharmaceutical company, today announces that on September 8, 2022, the Company’s Board of Directors (the “Board”) appointed Zahed Subhan PhD MBA JD as Chief Executive Officer of Adhera Therapeutics, effective September 30, 2022.

Codex DNA, Inc. today announced commercial release and first shipment of the BioXp™ 9600 system, a next-generation high throughput platform designed to revolutionize synthetic biology workflows.